导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.54% | 1383/4773 |
| 近一周 | -1.25% | 1890/5465 |
| 近一月 | -8.55% | 4983/5421 |
| 近一季 | -18.74% | 4804/5231 |
| 近半年 | -0.20% | 1430/4920 |
| 近一年 | 8.82% | 1274/4394 |
| 近两年 | 120.53% | 426/2954 |
| 近三年 | 72.58% | 318/2253 |
| 成立以来 | 115.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1868/4961 |
37.16% 854/5312 |
- - |
- - |
| 2025 | 51.77% 428/4813 |
-1.64% 2721/3635 |
3.39% 1023/4076 |
50.45% 306/4524 |
-0.80% 2649/4813 |
| 2024 | 14.83% 997/3463 |
-3.81% 1564/2808 |
-6.26% 1894/3014 |
29.41% 161/3129 |
-1.59% 1758/3463 |
| 2023 | -18.53% 1813/2656 |
2.21% 1406/2280 |
-7.03% 1761/2385 |
-9.43% 1826/2515 |
-5.33% 1322/2655 |
| 2022 | -28.41% 1554/2207 |
-19.50% 1467/1919 |
5.74% 834/2016 |
-18.06% 1676/2113 |
2.64% 874/2208 |
| 2021 | 14.47% 331/1822 |
-6.56% 1021/1255 |
26.94% 65/1330 |
-5.93% 878/1466 |
2.60% 556/1822 |
| 2020 | 67.03% 86/1250 |
3.97% 98/1028 |
30.54% 52/1067 |
6.33% 853/1164 |
15.73% 193/1184 |
| 2019 | - - |
- - |
-9.93% 702/804 |
7.69% 80/850 |
10.51% 126/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 平安创业板ETF VS. 长安沪深300非周期A(740101) |